|
EMA clarifies no scientific evidence to deter use of ibuprofen to manage coronavirus symptoms |
Medicines for Europe |
18 Mar 2020 |
Health & Consumers |
|
EU Pharmaceutical Strategy Roadmap: high time to improve patient access to medicines and to apply the lessons from COVID-19 |
Medicines for Europe |
04 Jun 2020 |
InfoSociety |
|
IQVIA Institute Scorecards show biosimilar medicines offer win for patients, policymakers and healthcare systems across Europe |
Medicines for Europe |
30 Jun 2020 |
Health & Consumers |
|
COVID-19 a lightning rod for major overhaul of EU pharmaceutical policy |
Medicines for Europe |
09 Jul 2020 |
Health & Consumers |
|
Decisive action on medicines shortages should be included in pharmaceutical and industrial strategies |
Medicines for Europe |
18 Sep 2020 |
Health & Consumers |
|
Now or never: pragmatism & ambition needed in EU pharma strategy to deliver on Europe’s medicines manufacturing |
Medicines for Europe |
07 Oct 2020 |
Health & Consumers |
|
Failure to launch: white paper explores the role of inappropriate use of IP in blocking access to generic and biosimilar medicines |
Medicines for Europe |
05 Nov 2020 |
Health & Consumers |
|
European Health Union – first step to greater EU solidarity in health crisis situations |
Medicines for Europe |
11 Nov 2020 |
Health & Consumers |
|
EU pharma strategy success depends on access to generic, biosimilar and value added medicines |
Medicines for Europe |
25 Nov 2020 |
Health & Consumers |
|
EU digital strategy requires investments in the digitalisation of Europe’s medicines regulatory agencies to succeed |
Medicines for Europe |
15 Jan 2021 |
Health & Consumers |
|
Window of opportunity to enhance EU regulatory systems wide open as EU pharma strategy prioritises stronger EU networks |
Medicines for Europe |
19 Jan 2021 |
Health & Consumers |
|
AESGP, EFPIA and Medicines for Europe reflections on the European Medicines Agency, the Heads of Medicines Agencies and the European Commission “Key principles for the use of electronic product information for EU medicines” |
Medicines for Europe |
03 Feb 2021 |
Health & Consumers |
|
Smarter use of generic, biosimilar and value added medicines will ensure equitable access to cancer care |
Medicines for Europe |
04 Feb 2021 |
Health & Consumers |
|
No further excuse to delay digital regulatory infrastructure for medicines after COVID-19 pandemic |
Medicines for Europe |
19 Feb 2021 |
Health & Consumers |
|
A new medicines trade and health security agenda for the European Commission |
Medicines for Europe |
19 Feb 2021 |
Health & Consumers |
|
EU must address barriers to continuous off-patent innovation and grasp opportunity for patients and healthcare |
Medicines for Europe |
23 Feb 2021 |
Health & Consumers |
|
Smart policies will encourage more critical medicines manufacturing in Europe |
Medicines for Europe |
26 Feb 2021 |
Health & Consumers |
|
New report reveals need for pricing and reimbursement and procurement reforms to ensure patient access and healthcare sustainability |
Medicines for Europe |
01 Mar 2021 |
Health & Consumers |
|
EU industrial policy can dramatically improve medicines manufacturing resilience and security of supply |
Medicines for Europe |
17 Mar 2021 |
Health & Consumers |
|
New report assesses progress on biosimilar medicine policies across Europe |
Medicines for Europe |
30 Mar 2021 |
Health & Consumers |
|
European patients need improved access to biosimilar medicines |
Medicines for Europe |
22 Apr 2021 |
Health & Consumers |
|
Off patent medicines essential for a fairer, healthier, and sustainable Europe says President Christoph Stoller |
Medicines for Europe |
30 Apr 2021 |
Health & Consumers |
|
EU Industrial strategy should be key to improving medicines supply chains |
Medicines for Europe |
17 May 2021 |
Health & Consumers |
|
Open borders that prioritise essential goods key to medicines supply in Europe |
Medicines for Europe |
02 Jun 2021 |
Health & Consumers |
|
EU must take the lead to ensure security of supply for medicines |
Medicines for Europe |
16 Jun 2021 |
Health & Consumers |
|
Orphan and paediatric reform should strive to improve access to medicine for rare disease patients and children |
Medicines for Europe |
30 Jul 2021 |
Health & Consumers |
|
HERA must address outstanding weaknesses in EU pharma framework to be successful |
Medicines for Europe |
16 Sep 2021 |
Health & Consumers |
|
Baton passes from Christoph Stoller to Rebecca Guntern as President of Medicines for Europe |
Medicines for Europe |
01 Oct 2021 |
Health & Consumers |
|
European Commission pilot project on repurposing brings value added innovation to life |
Medicines for Europe |
28 Oct 2021 |
Health & Consumers |
|
EU must learn from Covid-19 to improve crisis preparedness and response for the future |
Medicines for Europe |
09 Nov 2021 |
Health & Consumers |
